StemCell Therapy

The 69 rating InvestorsObserver gives to Chromadex Corp (CDXC) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 79 percent of stocks in the Biotechnology industry, CDXCs 69 overall rating means the stock scores better than 69 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 69 means the stock is more attractive than 69 percent of stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Chromadex Corp (CDXC) stock is higher by 5.28% while the S&P 500 is unchanged 0% as of 10:52 AM on Friday, Jul 10. CDXC is higher by $0.26 from the previous closing price of $5.00 on volume of 393,551 shares. Over the past year the S&P 500 is higher by 5.07% while CDXC is higher by 18.74%. CDXC lost -$0.51 per share the over the last 12 months.

To see InvestorsObserver's Sentiment Score for Chromadex Corp click here.

Read more:
Is Chromadex Corp (CDXC) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

This entry was posted on July 10, 2020 at 3:46 pm and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |